Pharmaceuticals and Biotech

  1. 05 Feb 2021  |  North America  |  Market Research

    Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market

    Early-stage R&D and Commercial Applications Fuel the Growth Pipeline

    The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...

    $4,950.00
  2. 19 Feb 2021  |  North America  |  Market Research

    Regulatory and Infrastructure Reforms in India and China Catalyzing the Asian Specialty Generics Market

    High Unmet Needs in Niche Oncology Indications will Drive Future Growth Potential

    Frost & Sullivans Transformational Health team provides critical insights into the Asian specialty generics market with this research service, highlighting growth opportunities, selected countries biopharmaceutical environment, and significant R&D, regulatory, and infrastructure reforms influencing its growth. The report examines similarities and c...

    $2,450.00
  3. 30 Apr 2021  |  North America  |  Tracker

    US COVID-19 Vaccines and Therapeutics Tracker—Market Insights and Trends, H1 2021

    Agnostic Vaccine Platform Technology Enhancing Future Growth Potential of Participants in the Value Chain

    This study by Frost & Sullivans Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. T...

    $2,450.00
  4. 13 May 2021  |  Global  |  Market Research

    Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market

    Increased Focus on Patient Centricity and Diversity in Clinical Trials Provide Growth Opportunities for CROs and Technology Vendors

    Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the markets maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs, a...

    $4,950.00
  5. 17 Jun 2021  |  North America  |  Market Research

    Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

    Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

    This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

    $4,950.00
  6. 23 Jun 2021  |  Global  |  Frost Radar

    Frost Radar™: Artificial Intelligence-enabled Drug Discovery in the Global Pharmaceutical Industry, 2021

    A Benchmarking System to Spark Companies to Action—Innovation that Fuels New Deal Flow and Growth Pipelines

    Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

    $4,950.00
  7. 30 Jun 2021  |  North America  |  Market Research

    US & EU Direct-to-consumer Genetic Testing Market, Key Trends & Growth Opportunities

    Telegenetic Counseling to Revolutionize Access to Patient Care

    In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

    $2,450.00
  8. 24 Aug 2021  |  North America  |  Market Research

    US and EU Biotech Industry VC Investment Growth Opportunities

    Future Growth Potential Driven by Next-generation Cell and Gene Platform Technology Powered by AI

    With this research service, Frost & Sullivan provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment. The study also identifies actionable growth opportunities for ...

    $2,450.00
  9. 27 Aug 2021  |  North America  |  Market Research

    US and EU Upstream Bioprocessing Growth Opportunities

    Increasing Demand for Consumables and Single-use Technologies to Drive Growth in Upstream Bioprocessing

    The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

    $4,950.00
  10. 13 Sep 2021  |  North America  |  Market Research

    Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities

    Emerging Pharmaceuticals and Highly Potent Complex Molecules Creating Future Growth Potential

    This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of...

    $4,950.00